Clinical Trial Review

August 2011 | Volume 10 | Issue 8 | Feature | 936 | Copyright © 2011

Abstract

Clinical Trial Review is a JDD department designed to provide physicians with information on drugs and devices undergoing clinical testing. It is our goal to inform the reader of the status of select drug and device studies relevant to the practice of dermatology before this information is available through standard channels. To participate in or learn more about these and additional trials, visit www.clinicaltrials.gov.

Purchase Original Article

Purchase a single fully formatted PDF of the original manuscript as it was published in the JDD.

Download the original manuscript as it was published in the JDD.

Contact a member of the JDD Sales Team to request a quote or purchase bulk reprints, e-prints or international translation requests.

To get access to JDD's full-text articles and archives, upgrade here.

Save an unformatted copy of this article for on-screen viewing.

Print the full-text of article as it appears on the JDD site.

→ proceed | ↑ close

PSORIASIS

T Cell Repertoire Analysis of Immune Mediated Skin Diseases

Sponsored by University of California, Davis. This study is designed to identify the cells of the immune system that cause skin disease such as psoriasis and mycosis fungoides. Blood samples from many patients will be compared in hopes of finding common cells and molecules responsible for skin diseases. Results of this study will increase our knowledge about immune mediated skin disease.

Peripheral blood with be collected from volunteers with psoriasis, mycosis fungoides and age matched controls. Fifteen tablespoons of blood will be collected prior to the initiation of treatment and again after the patient shows a clinical response to treatment. The time between blood draws will be no less than 3 months. There will be no more than two blood draws per patient. Blood samples will be used to determine the patient's HLA haplotype via PCR and DNA sequencing. After the patient's haplotype has been established the activated T cell repertoire will be analyzed for clonal expansions. Clonal expansions in the T cell repertoire will be determined by immunoscope analysis, which is a PCR based technique

Status: Currently recruiting participants as of June 2011.
ClinicalTrials.gov identifier: NCT00368784

table 1

ALOPECIA

Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia

Sponsored by GlaxoSmithKline. The purpose of this six month study is to show that dutasteride is safe and more effective than placebo, and at least as safe and effective as finasteride in treating hair loss in men with androgenetic alopecia. Three doses of dutasteride will be investigated.

Status: Currently recruiting participants as of July 2011.
ClinicalTrials.gov identifier: NCT01231607

table 2

Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss

Sponsored by Allergan. This study will evaluate the safety and efficacy of 3 doses of bimatoprost solution compared with vehicle and over-the-counter (OTC) minoxidil 2% solution in women with female pattern hair loss. All treatments will be provided in a double-blinded fashion except for minoxidil 2% solution which will be provided open-label.

Status: Not yet open for patient recruitment.
ClinicalTrials.gov identifier: NCT01325350

table 3

START: Swiss Taxotere Alopecia Prevention Trial

Sponsored by Sanofi-Aventis. Primary objective: Rate of complete chemotherapy induced alopecia (WHO grade III or IV, physician grading). Secondary objectives: Compliance with scalp cooling procedure; Received number of cycles of chemotherapy in each subgroup; Patient perception of scalp cooling procedure; and Side effects of scalp cooling systems.

Status: Currently recruiting patients as of May 2011.
ClinicalTrials.gov identifier: NCT01008774

table 4

↑ back to top


  • 1

Related Articles